These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 6386463)

  • 1. Heterogeneity of apparently pure anaerobic cultures: a possible source of error in susceptibility testing.
    Reig M; Baquero F
    Eur J Clin Microbiol; 1984 Aug; 3(4):323-4. PubMed ID: 6386463
    [No Abstract]   [Full Text] [Related]  

  • 2. Modified broth-disk surveillance of clindamycin-resistant Bacteroides fragilis group.
    Zar FA
    Antimicrob Agents Chemother; 1983 Jun; 23(6):947-9. PubMed ID: 6614896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of anaerobic bacteria to five antimicrobial agents and demonstration of resistance of Bacteroides fragilis to clindamycin.
    Sofianou D; Douboyas J; Papapanagiotou J; Paradelis AG
    Methods Find Exp Clin Pharmacol; 1982; 4(3):173-7. PubMed ID: 7121128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The microdilution antibiotic susceptibility test. Bacteroides fragilis.
    Steingrimsson O; Ryan RW; Tilton RC
    Am J Clin Pathol; 1976 Jun; 65(6):1010-5. PubMed ID: 1047602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility studies in the Bacteroides fragilis group resistant to clindamycin.
    Liñares J; Pérez JL; Martín R
    J Antimicrob Chemother; 1983 Sep; 12(3):293. PubMed ID: 6630117
    [No Abstract]   [Full Text] [Related]  

  • 6. High prevalence of resistance to clindamycin in Bacteroides fragilis group isolates.
    Oteo J; Aracil B; Alós JI; Gómez-Garcés JL
    J Antimicrob Chemother; 2000 May; 45(5):691-3. PubMed ID: 10797095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.
    Fernández Canigia L; Castello L; Di Martino A; Greco G; Legaria MC; Litterio M; Predari SC; Rollet R; Rossetti A; Carloni G; Sarchi MI; Bianchini H
    Rev Argent Microbiol; 2007; 39(3):156-60. PubMed ID: 17987852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased resistance of encapsulated Bacteroides fragilis to clindamycin.
    Brook I; Gillmore JD
    Chemotherapy; 1994; 40(1):16-20. PubMed ID: 8306810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clindamycin resistance in Bacteroides fragilis.
    Tally FP; Sosa A; Jacobus NV; Malamy MH
    J Antimicrob Chemother; 1981 Dec; 8 Suppl D():43-8. PubMed ID: 7338489
    [No Abstract]   [Full Text] [Related]  

  • 10. Epidemiology of clindamycin resistance in the Bacteroides fragilis group.
    Reig M; Campello MG; Baquero F
    J Antimicrob Chemother; 1984 Dec; 14(6):595-603. PubMed ID: 6520060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standardization of antimicrobial disc susceptibility test for anaerobic bacteria.
    Ho SW
    Zhonghua Min Guo Wei Sheng Wu Xue Za Zhi; 1976 Dec; 9(3-4):55-62. PubMed ID: 1037535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacteroides fragilis resistant to metronidazole, clindamycin and cefoxitin.
    Brogan O; Garnett PA; Brown R
    J Antimicrob Chemother; 1989 Apr; 23(4):660-2. PubMed ID: 2745269
    [No Abstract]   [Full Text] [Related]  

  • 13. Clindamycin resistance in anaerobic bacteria.
    Tally FP; Cuchural GJ; Bieluch VM; Jacobus NV; Malamy MH
    Scand J Infect Dis Suppl; 1984; 43():34-43. PubMed ID: 6598519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of microdilution trays (sensititre) for antimicrobial susceptibility testing of Bacteroides fragilis.
    Dornbusch K; Lindmark A; Nord CE
    Med Microbiol Immunol; 1978 Oct; 165(3):147-51. PubMed ID: 723780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of subinhibitory concentrations of clindamycin on the morphological, biochemical and genetic characteristics of Bacteroides fragilis.
    Silvestro EM; Nakano V; Arana-Chavez VE; Marques MV; Avila-Campos MJ
    FEMS Microbiol Lett; 2006 Apr; 257(2):189-94. PubMed ID: 16553852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
    Goldstein EJ; Citron DM; Cherubin CE; Hillier SL
    J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bacteroides fragilis. Its isolation and antibiotic sensitivity].
    Cancet B; Nadaud M
    Ann Biol Clin (Paris); 1976; 34(2):133-7. PubMed ID: 970703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined activity of clindamycin and gentamicin on Bacteroides fragilis and other bacteria.
    Okubadejo OA; Allen J
    J Antimicrob Chemother; 1975 Dec; 1(4):403-9. PubMed ID: 812858
    [No Abstract]   [Full Text] [Related]  

  • 19. Disc diffusion method to screen for high-level resistance to clindamycin and erythromycin in the Bacteroides fragilis group.
    Callihan DR; Nolte FS
    Diagn Microbiol Infect Dis; 1985 Mar; 3(2):131-7. PubMed ID: 3979019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical significance of clindamycin-resistant Bacteroides fragilis.
    Yee MH; Guiney DG; Hasegawa P; Davis CE
    JAMA; 1982 Oct; 248(15):1860-1. PubMed ID: 7120605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.